Glenmark Pharmaceuticals closed the third quarter of FY26 with consolidated revenue of Rs. 3,900 crore, a 15.1% jump compared to the same period last year. The numbers suggest the company is gaining ground across multiple fronts, with India and North America doing the heavy lifting.
India Formulations, Glenmark’s largest segment, was the standout. Revenue here climbed 22.1% year-on-year to Rs. 1,298 crore, driven by strength in the company’s core therapy areas. North America was not far behind, posting a 24.2% rise to Rs. 970 crore, though that figure includes out-licensing income from ISB 2001. Strip that out and the underlying growth story still holds, particularly with new product launches adding momentum to the portfolio.
Europe and Emerging Markets grew at a steadier pace, with revenues rising 9.1% and 8.4% respectively to Rs. 796 crore and Rs. 811 crore. Neither segment posted headline-grabbing numbers, but both showed signs of improved momentum, especially in Europe, where the respiratory franchise is gaining traction.
The profitability story was even sharper. EBITDA came in at Rs. 869 crore, a 44.9% year-on-year increase, with margins expanding to 22.3%. Profit after tax rose 15.9% to Rs. 403 crore, with a PAT margin of 10.3%. The fact that profits grew faster than revenue tells investors that Glenmark is not just chasing top-line growth but actually improving the quality of its earnings.
Glenn Saldanha, Chairman and Managing Director, kept his commentary focused on execution and pipeline. “India continued to outperform in our core therapies,” he said. “In North America, we advanced our portfolio through new launches and pipeline progression, and we saw a positive regulatory outcome at Monroe.” He sounded confident about the direction, adding that the innovative side of the business is starting to take shape as a meaningful growth engine.
On the product side, RYALTRIS is scaling across markets and appears to be gaining commercial traction. WINLEVI, Glenmark’s acne treatment, is picking up in the UK and has now received regulatory approval across Europe. The oncology pipeline, which includes partnered assets like QiNHAYO and Trastuzumab Rezetecan, is aimed at high-need markets where Glenmark does not yet have a significant footprint.
Saldanha framed the quarter as part of a deliberate shift in how the company sees itself. “We are building a more innovation-led Glenmark,” he said, pointing to a growth trajectory that relies less on generics and more on differentiated products and licensing deals.
The results put Glenmark on track to meet its near-term guidance, according to management. For a company that has spent years repositioning itself away from pure volume-driven pharma, this quarter looks like a credible step in that direction. The real test will be whether the pipeline converts into sustained profit growth over the next few quarters, and whether the North America momentum holds without the one-off licensing income.
